Free Trial

Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis

+0.44 (+4.64%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
4.54 million shs
Average Volume
3.16 million shs
Market Capitalization
$1.15 billion
P/E Ratio
Dividend Yield
Price Target

Arcutis Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
172.2% Upside
$27.00 Price Target
Short Interest
18.74% of Shares Sold Short
Dividend Strength
News Sentiment
0.80mentions of Arcutis Biotherapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$110,418 Sold Last Quarter
Proj. Earnings Growth
From ($2.07) to ($1.35) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.53 out of 5 stars

Medical Sector

694th out of 920 stocks

Pharmaceutical Preparations Industry

320th out of 423 stocks

ARQT stock logo

About Arcutis Biotherapeutics Stock (NASDAQ:ARQT)

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

ARQT Stock Price History

ARQT Stock News Headlines

Q1 2024 Arcutis Biotherapeutics Inc Earnings Call
Arcutis Biotherapeutics Inc Ordinary Shares ARQT
See More Headlines
Receive ARQT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$59.61 million
Book Value
$1.94 per share


Free Float
Market Cap
$1.15 billion

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Todd Franklin Watanabe M.A.Mr. Todd Franklin Watanabe M.A. (Age 56)
    President, CEO & Director
    Comp: $1.01M
  • Dr. Bhaskar Chaudhuri Ph.D. (Age 69)
    Co-Founder & Independent Director
    Comp: $60.83k
  • Dr. Patrick E. Burnett M.D. (Age 52)
    Ph.D., Senior VP & Chief Medical Officer
    Comp: $722.94k
  • Mr. L. Todd Edwards (Age 60)
    Senior VP & Chief Commercial Officer
    Comp: $755.64k
  • Mr. David J. Topper (Age 66)
    Senior VP & Chief Financial Officer
  • Mr. Rajvir Madan
    Chief Digital & Technology Officer
  • Ms. Latha Vairavan
    Vice President of Finance & Investor Relations
  • Ms. Courtney Barton (Age 41)
    VP and Chief Compliance Officer & Privacy Officer
  • Mr. Masaru Matsuda Esq. (Age 53)
    J.D., Senior VP, General Counsel & Corporate Secretary
    Comp: $626.22k
  • Ms. Amanda Sheldon
    Head of Corporate Communications

ARQT Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcutis Biotherapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARQT shares.
View ARQT analyst ratings
or view top-rated stocks.

What is Arcutis Biotherapeutics' stock price target for 2024?

8 brokers have issued twelve-month price objectives for Arcutis Biotherapeutics' shares. Their ARQT share price targets range from $8.00 to $50.00. On average, they anticipate the company's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 172.2% from the stock's current price.
View analysts price targets for ARQT
or view top-rated stocks among Wall Street analysts.

How have ARQT shares performed in 2024?

Arcutis Biotherapeutics' stock was trading at $3.23 at the start of the year. Since then, ARQT shares have increased by 207.1% and is now trading at $9.92.
View the best growth stocks for 2024 here

When is Arcutis Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our ARQT earnings forecast

How were Arcutis Biotherapeutics' earnings last quarter?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) posted its earnings results on Tuesday, May, 14th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.28. The firm had revenue of $49.57 million for the quarter. Arcutis Biotherapeutics had a negative trailing twelve-month return on equity of 197.28% and a negative net margin of 204.35%. During the same quarter in the previous year, the business posted ($1.31) EPS.

What ETFs hold Arcutis Biotherapeutics' stock?

ETFs with the largest weight of Arcutis Biotherapeutics (NASDAQ:ARQT) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH).SPDR S&P Biotech ETF (XBI).

What other stocks do shareholders of Arcutis Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

When did Arcutis Biotherapeutics IPO?

Arcutis Biotherapeutics (ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Cantor was co-manager.

Who are Arcutis Biotherapeutics' major shareholders?

Arcutis Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (10.54%), Vanguard Group Inc. (4.47%), Bain Capital Life Sciences Investors LLC (1.74%), StemPoint Capital LP (0.00%), Ikarian Capital LLC (0.51%) and AMI Asset Management Corp (0.36%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Larry Todd Edwards, Life Sciences Viii L Frazier, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends

How do I buy shares of Arcutis Biotherapeutics?

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARQT) was last updated on 5/23/2024 by Staff

From Our Partners